文献速递临床试验与 GCP

头皮冷却装置对乳腺癌化疗女性脱发的影响:SCALP随机临床试验

Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

这项多中心随机临床试验在美国7个中心纳入182例需化疗的乳腺癌女性,随机分为头皮冷却组(n=119)和对照组(n=63)。中期分析时142例可评估,冷却组48/95例(50.5%;95%CI 40.7%-60.4%)成功保留头发,对照组0/47例(0%;95%CI 0%-7.6%),成功率差50.5%(95%CI 40.5%-60.6%),单侧Fisher精确检验P<.001,跨过优效界值(P=.0061),数据与安全监察委员会建议终止研究。

要点

  • 冷却组48/95例(50.5%)成功保留头发,对照组0/47例(0%),成功率差50.5%(95%CI 40.5%-60.6%)。
  • 冷却组报告54例不良事件,均为1级和2级,无严重器械不良事件。
  • 生活质量各量表从基线至第4周期变化在两组间无统计学显著差异。

核心结论

  • 在接受紫杉类、蒽环类或两者联合化疗的I至II期乳腺癌女性中,头皮冷却组第4周期化疗后头发丢失少于50%的可能性显著高于未冷却组。
  • 需要进一步研究评估长期疗效和不良反应。

研究设计与样本

  • 多中心随机临床试验,在美国7个中心开展,2013年12月9日至2016年9月30日入组182例需化疗的乳腺癌女性。
  • 参与者随机分为头皮冷却组(n=119)和对照组(n=63),预设一次中期分析以便因优效提前终止,报告数据来自该中期分析。

主要发现

  • 中期分析时142例可评估,患者平均(SD)年龄52.6(10.1)岁;36%(n=51)接受蒽环类化疗,64%(n=91)接受紫杉类化疗。
  • 冷却组48/95例成功保留头发(50.5%;95%CI 40.7%-60.4%),对照组0/47例(0%;95%CI 0%-7.6%),成功率差50.5%(95%CI 40.5%-60.6%)。
  • 单侧Fisher精确检验P<.001,跨过优效界值(P=.0061),数据与安全监察委员会于2016年9月26日建议终止研究。
  • 生活质量各量表从基线至第4周期化疗的变化在头皮冷却组与对照组间均无统计学显著差异。
  • 仅收集与器械使用相关的不良事件;冷却组报告54例不良事件,均为1级和2级,无严重器械不良事件。

关键数值与推荐

  • 主要疗效终点为第4周期化疗结束时由不知治疗分组的临床医生采用常见不良事件评价标准4.0版量表评估的成功头发保留(0级[无脱发]或1级[<50%脱发且不需戴假发]视为保留头发)。
  • 次要终点包括假发使用以及欧洲癌症研究与治疗组织生活质量问卷核心30、医院焦虑抑郁量表和体象量表汇总评分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 报告数据来自预设中期分析。
  • 需要进一步研究评估长期疗效和不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chemotherapy may induce alopecia. Although scalp cooling devices have been used to prevent this alopecia, efficacy has not been assessed in a randomized clinical trial. OBJECTIVES: To assess whether a scalp cooling device is effective at reducing chemotherapy-induced alopecia and to assess adverse treatment effects. DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial of women with breast cancer undergoing chemotherapy. Patients were enrolled from December 9, 2013, to September 30, 2016. One interim analysis was planned to allow the study to stop early for efficacy. Data reported are from the interim analysis. This study was conducted at 7 sites in the United States, and 182 women with breast cancer requiring chemotherapy were enrolled and randomized. INTERVENTIONS: Participants were randomized to scalp cooling (n = 119) or control (n = 63). Scalp cooling was done using a scalp cooling device. MAIN OUTCOMES AND MEASURES: The primary efficacy end points were successful hair preservation assessed using the Common Terminology Criteria for Adverse Events version 4.0 scale (grade 0 [no hair loss] or grade 1 [<50% hair loss not requiring a wig] were considered to have hair preservation) at the end of 4 cycles of chemotherapy by a clinician unaware of treatment assignment, and device safety. Secondary end points included wig use and scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, Hospital Anxiety and Depression Scale, and a summary scale of the Body Image Scale. RESULTS: At the time of the interim analysis, 142 participants were evaluable. The mean (SD) age of the patients was 52.6 (10.1) years; 36% (n = 51) received anthracycline-based chemotherapy and 64% (n = 91) received taxane-based chemotherapy. Successful hair preservation was found in 48 of 95 women with cooling (50.5%; 95% CI, 40.7%-60.4%) compared with 0 of 47 women in the control group (0%; 95% CI, 0%-7.6%) (success rate difference, 50.5%; 95% CI, 40.5%-60.6%). Because the 1-tailed P value from the Fisher exact test was <.001, which crossed the superiority boundary (P = .0061), the data and safety monitoring board recommended study termination on September 26, 2016. There were no statistically significant differences in changes in any of the scales of quality of life from baseline to chemotherapy cycle 4 among the scalp cooling and control groups. Only adverse events related to device use were collected; 54 adverse events were reported in the cooling group, all grades 1 and 2. There were no serious adverse device events. CONCLUSIONS AND RELEVANCE: Among women with stage I to II breast cancer receiving chemotherapy with a taxane, anthracycline, or both, those who underwent scalp cooling were significantly more likely to have less than 50% hair loss after the fourth chemotherapy cycle compared with those who received no scalp cooling. Further research is needed to assess longer-term efficacy and adverse effects. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01986140.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Nangia J, Wang T, Osborne C, et al. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017. PMID: 28196254. doi:10.1001/jama.2016.20939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。